Gilead Sciences posted fourth-quarter results that exceeded Wall Street estimates on Tuesday as its HIV drug sales rose 16% ...

Gilead said its fourth-quarter HIV product sales rose to $5.45 billion from $4.69 billion a year earlier, due to higher ...

Shares of Gilead Sciences Inc. advanced 7.46% to $103.31 Wednesday, on what proved to be an all-around poor trading session ...

Q4 2024 Earnings Call Feb 11, 2025, 4:30 p.m. ET. Contents: Prepared Remarks. Questions and Answers. Call Participant ...

Big drug maker Gilead expects to take a billion-dollar hit this year via drug-pricing provisions in the Inflation Reduction ...

Shares of Gilead Sciences ( GILD 7.46%) were jumping 7.9% higher on Wednesday at 11:34 a.m. The solid gain came after the big ...

Gilead Sciences reported strong fourth-quarter earnings with significant growth in its HIV and oncology segments.

Gilead Sciences faces revenue growth challenges as its blockbuster drugs lose exclusivity by 2033. Check out my ...

Gilead Sciences, Inc. (NASDAQ:GILD – Get Free Report)’s share price reached a new 52-week high during mid-day trading on Wednesday following a better than expected earnings announcement. The company ...

Gilead Sciences is rated a Strong Buy due to strong Q4 2024 results and a robust HIV franchise. Check out my 12-month price ...

Robinhood reported fourth-quarter revenue of $1.01 billion, up 115% year-over-year and a new company record. The revenue ...

Andrew Dickinson, the Chief Financial Officer of Gilead Sciences, Inc. (NASDAQ:GILD), recently executed a series of transactions involving the company's stock. On February 12, Dickinson sold 137,676 ...